DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
CDC Office of Financial Resources
2820 Brandywine Road
Atlanta, GA 30341

NOTICE OF AWARD
AUTHORIZATION (Legislation/Regulations)
Section 317K of the Public Health Service Act, [42 U.S.C. 247b-12], as amended

TITILE OF PROJECT (OR PROGRAM)
COMPONENT A - MISSOURI PREGNANCY RISK ASSESSMENT MONITORING SYSTEM

GRANTEE NAME AND ADDRESS
HEALTH AND SENIOR SERVICES, MISSOURI DEPARTMENT OF
Alternate Name: MISSOURI STATE DEPT/ HEALTH & SENIOR Srv
2900 WILMINGTON DR
JEFFERSON CITY, MO 65102-0570

10a. GRANTEE AUTHORIZING OFFICIAL
Ms. Tonya J. Loucks
920 WILMINGTON DR
JEFFERSON CITY, MO 65109-5796
Phone: 573-751-6014

GRANTEE PROJECT DIRECTOR
Venkata Garikapity
920 Wildwood Drive
Jefferson City, MO 65102-0570
Phone: 573-526-0452

10b. FEDERAL PROJECT OFFICER
Sue Shaw
4770 Buford Hwy NE
Atlanta, GA 30341
Phone: 770-488-6142

11. APPROVED BUDGET (Excludes Direct Assistance)
Financial Assistance from the Federal Awarding Agency Only
Total project costs including grant funds and all other financial participation

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salaries and Wages</td>
<td>81,093.00</td>
</tr>
<tr>
<td>Fringe Benefits</td>
<td>4,427.00</td>
</tr>
<tr>
<td>Total Personnel Costs</td>
<td>125,370.00</td>
</tr>
<tr>
<td>Equipment</td>
<td>0.00</td>
</tr>
<tr>
<td>Supplies</td>
<td>3,164.00</td>
</tr>
<tr>
<td>Travel</td>
<td>2,815.00</td>
</tr>
<tr>
<td>Construction</td>
<td>0.00</td>
</tr>
<tr>
<td>Other</td>
<td>27,849.00</td>
</tr>
<tr>
<td>Contractual</td>
<td>48,064.00</td>
</tr>
<tr>
<td>TOTAL DIRECT COSTS</td>
<td>207,262.00</td>
</tr>
<tr>
<td>INDIRECT COSTS</td>
<td>26,788.00</td>
</tr>
<tr>
<td>TOTAL APPROVED BUDGET</td>
<td>234,050.00</td>
</tr>
</tbody>
</table>

12. AWARD COMPUTATION
a. Amount of Federal Financial Assistance (from item 11a) | 234,050.00 |
b. Less Unobligated Balance From Prior Budget Periods | 0.00 |
c. Less Cumulative Prior Award(s) This Budget Period | 157,050.00 |
d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION | 77,000.00 |

13. Total Federal Funds Awarded to Date for Project Period | 595,600.00 |

REMARKS (Other Terms and Conditions Attached) | Yes | No |

14. RECOMMENDED FUTURE SUPPORT
(Subject to the availability of funds and satisfactory progress of the project): |

YEAR | TOTAL DIRECT COSTS | YEAR | TOTAL DIRECT COSTS
--- | --- | --- | ---
   | a. | b. | c. | d. | e. | f. | g. | h. | i. | j. | k. | l. | m. | n. | o. | p. |
 1   | 234,050.00 | 234,050.00 |
 2   | 0.00 | 0.00 |
 3   | 0.00 | 0.00 |
 4   | 0.00 | 0.00 |
 5   | 0.00 | 0.00 |
 6   | 0.00 | 0.00 |
 7   | 0.00 | 0.00 |
 8   | 0.00 | 0.00 |
 9   | 0.00 | 0.00 |
 10  | 0.00 | 0.00 |

15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:
   a. REVENUE
   b. ADDITIONAL COSTS
   c. MATCHING
   d. OTHER RESEARCH (Add / Delete Options)
   e. OTHER (See REMARKS)

16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND APPROVED BY, THE FEDERAL AWARDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:
   a. The grant program regulations.
   b. The grant program regulations.
   c. This award notice including terms and conditions, if any, noted above under REMARKS.
   d. Federal administrative requirements, cost principles and audit requirements applicable to the grant.

In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantees when funds are drawn or otherwise obtained from the grant payment system.
AWARD ATTACHMENTS

MISSOURI STATE DEPT/ HEALTH & SENIOR SRV

1. Terms and Conditions - PRAMS Opioid Disability Supplement
NOTICE OF FUNDING OPPORTUNITY (NOFO) NUMBER: DP16-001
Amendment 2

ADDITIONAL TERMS AND CONDITIONS OF THIS AWARD

SUPPLEMENT: The purpose of this revised Notice of Award (NOA) is to authorize supplemental funds in the amount of $77,000 for the period 9/30/2018-4/30/2019. This action is taken in accordance with the recipient’s application dated August 3, 2018.

Opioid Funds and Availability: Opioid Crisis Funding in the amount of $14,700 (Module A) and $37,000 (Module B) is approved for this award under for budget period September 30, 2018 through April 30, 2019.

The budget is approved as follows:

<table>
<thead>
<tr>
<th>Budget Category</th>
<th>Current Award</th>
<th>Opioid Supplement Mod A</th>
<th>Opioid Supplement Mod B</th>
<th>Disability Supplement</th>
<th>Revised Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salaries &amp; Wages</td>
<td>$55,115</td>
<td>$6,618</td>
<td>$12,742</td>
<td>$6,618</td>
<td>$81,093</td>
</tr>
<tr>
<td>Fringe Benefits</td>
<td>$29,211</td>
<td>$3,838</td>
<td>$7,390</td>
<td>$3,838</td>
<td>$44,277</td>
</tr>
<tr>
<td>Equipment</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td>Supplies</td>
<td>$3,164</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$3,164</td>
</tr>
<tr>
<td>Contractual</td>
<td>$48,064</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$48,064</td>
</tr>
<tr>
<td>Consulting</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td>Travel</td>
<td>$893</td>
<td>$0</td>
<td>$1,882</td>
<td>$40</td>
<td>$2,815</td>
</tr>
<tr>
<td>Other</td>
<td>$2,557</td>
<td>$2,017</td>
<td>$10,698</td>
<td>$12,577</td>
<td>$27,849</td>
</tr>
<tr>
<td>Total Direct</td>
<td>$139,004</td>
<td>$12,473</td>
<td>$32,712</td>
<td>$23,073</td>
<td>$207,262</td>
</tr>
<tr>
<td>Indirect Costs</td>
<td>$18,046</td>
<td>$2,227</td>
<td>$4,288</td>
<td>$2,227</td>
<td>$26,788</td>
</tr>
<tr>
<td>Total Costs</td>
<td>$157,050</td>
<td>$14,700</td>
<td>$37,000</td>
<td>$25,300</td>
<td>$234,050</td>
</tr>
</tbody>
</table>

FFR Reporting: The recipient is required to report separately on the use of opioid funds on the Federal Financial Report (FFR). The recipient must submit an annual FFR as indicated in the Reporting Requirements section of the General Terms and Conditions, and the recipient must attach a document to their FFR submission to reflect expenditures by subaccount.

Additional Reporting Requirement for Disability Funds: The recipient is required to include the amount of disability funds authorized in the remarks section of the FFR (block 12).

HUMAN SUBJECTS RESTRICTION(s): Research involving human subjects cannot begin until a copy of the IRB approval letter for each of the institution sites is submitted to the Grants Management Specialist.

A 10 % funding restriction in the amount of $1,470 has been placed on this award pending receipt of an IRB approval letter for DP16-001 PRAMS: Supplemental Opioid and Disability Research Module A: Opioid Questionnaire.

A 10 % funding restriction in the amount of $3,700 has been placed on this award pending receipt of an IRB approval letter for DP16-001 PRAMS: Supplemental Opioid and Disability Research Module B:
Opioid Call-Back Survey.

A 10% funding restriction in the amount of $2,530 has been placed on this award pending receipt of an IRB approval letter for DP16-001 PRAMS: Supplemental Opioid and Disability Research Module C: Disability Questionnaire.

TECHNICAL REVIEW STATEMENT RESPONSE REQUIREMENT: The review comments on the strengths and weaknesses of the proposal are provided as part of this award. A response to the weaknesses in these statements must be submitted to and approved, in writing, by the Grants Management Specialist/Grants Management Officer (GMS/GMO) noted in the Staff Contacts section of this NoA, no later than 30 days from the budget period start date. Failure to submit the required information by the due date, October 30, 2018, will cause delay in programmatic progress and will adversely affect the future funding of this project.

Module A:

- While the applicant provided current core PRAMS IRB approval documentation and assurance, a description of procedures for human subjects protection, as specified on page 20 of the guidance document “PRAMS Opioid_Disability Supplement Guidance_FINAL revised_7-26-18”, was not included in the application. The applicant should justify the involvement of human subjects and proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials. Please note, in item 5, the applicant should indicate that PRAMS is not a clinical trial. (PHS 398 Research Plan/ Human Subjects Section/Protection of Human Subjects - page 1)

- Applicant should address inclusion of women and minorities according to pages 20-21 of the guidance document.

Module B:

- While the applicant provided current core PRAMS IRB approval documentation and assurance, a description of procedures for human subjects protection, as specified on page 20 of the guidance document “PRAMS Opioid_Disability Supplement Guidance_FINAL revised_7-26-18”, was not included in the application. The applicant should justify the involvement of human subjects and proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials. Please note, in item 5, the applicant should indicate that PRAMS is not a clinical trial. (PHS 398 Research Plan/ Human Subjects Section/Protection of Human Subjects - page 1)

Module C:

- While the applicant provided current core PRAMS IRB approval documentation and assurance, a description of procedures for human subjects protection, as specified on page 20 of the guidance document “PRAMS Opioid_Disability Supplement Guidance_FINAL revised_7-26-18”, was not included in the application. The applicant should justify the involvement of human subjects and proposed protections from research risk relating to their participation according to the following five review criteria:
1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials. Please note, in item 5, the applicant should indicate that PRAMS is not a clinical trial. (PHS 398 Research Plan/ Human Subjects Section/Protection of Human Subjects - page 1)

- Applicant should address inclusion of women and minorities according to pages 20-21 of the guidance document.

- The application should revise work plan to include the following activities that should occur from March – April 2019: State priorities identified, plans for convening a meeting of key stakeholders outlined, and brief report of initial operational data developed from the supplement

**PAYMENT MANAGEMENT SYSTEM SUBACCOUNT:** Effective October 1, 2013, a new HHS policy on subaccounts requires the CDC setup payment subaccounts within the Payment Management System (PMS) for all new grant awards. Funds awarded in support of approved activities have been obligated in a newly established subaccount in the PMS, herein identified as the "P Account". A "P" Account is a subaccount created specifically for the purpose of tracking designated types of funding in the PMS.

All award funds must be tracked and reported separately. Funds must be used in support of approved activities in the FOA and the approved application.

The grant document number and subaccount title (below) must be known in order to draw down funds from this P Account.

**Grant Document Number:** 16DP006213180CDP

Please be advised that the recipient must exercise proper stewardship over Federal funds by ensuring that all cost charged to their cooperative agreement are allowable, allocable, necessary, and reasonable.

All other terms and conditions issued with the original Notice of Award remain in effect throughout the budget period unless changed, in writing, by the CDC Grants Management Officer.

PLEASE REFERENCE THE GRANT NUMBER ON ALL CORRESPONDENCE.

Natasha Jones  
Grants Management Specialist (GMS)  
Office of Grants Services (OGS)  
Office of Financial Resources (OFR)  
Office of the Chief Operating Officer (OCOO)  
Centers for Disease Control and Prevention (CDC)  
Njones6@cdc.gov | 770-488-1649

Patricia French  
Grants Management Officer (GMO)  
Office of Grants Services (OGS)  
Office of Financial Resources (OFR)  
Office of the Chief Operating Officer (OCOO)